The need to seek improved combined oral contraceptive (COC) efficacy, with fewer health
risks and better acceptability, has been ongoing since the introduction of COCs more than …

Background Concern about estrogen‐related adverse effects has led to progressive
reductions in the estrogen dose in combination oral contraceptives (COCs). However …

Objectives To compare the effects of a combined oral contraceptive (COC) containing
nomegestrol acetate and 17β-oestradiol (NOMAC/E2) on haemostasis, lipids, carbohydrate …

For many years, it has been well documented that combined hormonal contraceptives
increase the risk of venous thromboembolism (VTE). The third-generation pill use …

Background Thrombin generation (TG) assays evaluate the balance between pro‐and
anticoagulant forces, to better assess bleeding and thrombotic risks. Although TG readouts …

Background People who have or had the potential to menstruate (PPM) with inherited
bleeding disorders (BD) face particular challenges receiving appropriate diagnosis and care …

Objective A systematic review of studies published between January 1995 and April 2010
aimed at determining the effect of combined hormonal contraceptives (CHCs), administered …

Dienogest (DNG) is a 19-nortestosterone derivative (a C-19 progestogen) with a
cyanomethyl instead of an ethinyl group at the C-17 position, which may make the …

Introduction Contraceptives containing ethinylestradiol (EE) induce changes in the
coagulation system and are associated with a risk of venous thromboembolism. However …

Introduction: The pharmacodynamic effects of various combined oral estrogen-progestin
combinations (COC) are examined for their components alone or in the various combined …